Vanguard Group Inc. Buys 242,220 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Vanguard Group Inc. lifted its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 10.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,596,119 shares of the company's stock after acquiring an additional 242,220 shares during the period. Vanguard Group Inc. owned 4.40% of Replimune Group worth $44,420,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Replimune Group by 99.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,509 shares of the company's stock valued at $26,000 after buying an additional 752 shares in the last quarter. Quantbot Technologies LP increased its stake in Replimune Group by 498.0% in the 2nd quarter. Quantbot Technologies LP now owns 5,980 shares of the company's stock worth $104,000 after purchasing an additional 4,980 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Replimune Group during the 1st quarter worth about $106,000. BNP Paribas Arbitrage SA lifted its stake in Replimune Group by 157.6% during the second quarter. BNP Paribas Arbitrage SA now owns 6,391 shares of the company's stock valued at $112,000 after buying an additional 3,910 shares in the last quarter. Finally, Point72 Hong Kong Ltd boosted its holdings in shares of Replimune Group by 369.7% in the first quarter. Point72 Hong Kong Ltd now owns 6,919 shares of the company's stock worth $117,000 after buying an additional 5,446 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Down 4.4 %

Shares of Replimune Group stock traded down $0.32 during trading on Wednesday, hitting $6.96. The stock had a trading volume of 913,824 shares, compared to its average volume of 1,403,377. Replimune Group, Inc. has a 1 year low of $5.89 and a 1 year high of $24.81. The stock has a 50 day simple moving average of $8.03 and a 200 day simple moving average of $9.97. The company has a quick ratio of 12.40, a current ratio of 12.40 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $427.27 million, a PE ratio of -2.19 and a beta of 1.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.12. On average, research analysts expect that Replimune Group, Inc. will post -3.28 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.